Advertisement
Advertisement
CRDL
Cardiol Therapeutics Inc. Class A Common Shares
0.99
USDSponsored
+0.07
+7.39%
Nov 06, 15:59 UTC -5
Closed
After-Market
0.99
-0.01
-0.90%
Cardiol Therapeutics Inc. Class A Common Shares (CRDL) Earnings
CRDL Earnings Reports
Positive Surprise Ratio
CRDL beat 18 of 24 last estimates.
75%
Next Report
In 2 Days
Date of Next Report
Nov 11, 2026
Estimate for Q3 26 (Revenue/ EPS)
--
/-$0.08
Implied change from Q2 26 (Revenue/ EPS)
--
/+60.00%
Implied change from Q3 25 (Revenue/ EPS)
--
/-33.33%
Cardiol Therapeutics Inc. Class A Common Shares earnings per share and revenue
On Aug 12, 2026, CRDL reported earnings of -0.05 USD per share (EPS) for Q2 26, beating the estimate of -0.10 USD, resulting in a 53.31% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a +12.50% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 3 analysts forecast an EPS of -0.08 USD, with revenue projected to reach -- USD, implying an increase of 60.00% EPS, and increase of 0.00% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Cronos Group Inc. Common Share
Report Date
Nov 05, 2026 For Q3 26
Estimate
$0.03
Actual
$0.04
Surprise
+17.65%
Aclaris Therapeutics, Inc.
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.16
Actual
-$0.12
Surprise
+28.49%
Protara Therapeutics, Inc. Common Stock
Report Date
Nov 06, 2026 For Q3 26
Estimate
-$0.37
Actual
-$0.35
Surprise
+6.17%
Minerva Neurosciences, Inc
Report Date
Nov 06, 2026 For Q3 26
Estimate
-$0.12
Actual
$1.94
Surprise
+1,629.97%
Organogenesis Holdings Inc. Class A Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.17
Actual
-$0.25
Surprise
-40.06%
ZOETIS INC.
Report Date
Nov 05, 2026 For Q3 26
Estimate
$1.52
Actual
$1.75
Surprise
+14.64%
Dyne Therapeutics, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.92
Actual
-$1.06
Surprise
-15.57%
Amylyx Pharmaceuticals, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.38
Actual
-$0.38
Surprise
+1.04%
Aldeyra Therapeutics, Inc.
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.09
Actual
-$0.06
Surprise
+37.43%
Lipocine Inc.
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.36
Actual
-$0.08
Surprise
+77.91%
FAQ
What were Cardiol Therapeutics Inc. Class A Common Shares's earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, Cardiol Therapeutics Inc. Class A Common Shares reported EPS of -$0.05, beating estimates by 53.31%, and revenue of $0.00, 0% as expectations.
How did the market react to Cardiol Therapeutics Inc. Class A Common Shares's Q2 2026 earnings?
The stock price moved up 12.5%, changed from $1.52 before the earnings release to $1.71 the day after.
When is Cardiol Therapeutics Inc. Class A Common Shares expected to report next?
The next earning report is scheduled for Nov 11, 2026.
What are the forecasts for Cardiol Therapeutics Inc. Class A Common Shares's next earnings report?
Based on 3
analysts, Cardiol Therapeutics Inc. Class A Common Shares is expected to report EPS of -$0.08 and revenue of -- for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.